Matrix metalloproteinases--a conceptional alternative for disease-modifying strategies in ALS/MND?
Ludolph
Albert C
AC
Department of Neurology, University of Ulm, Oberer Eselsberg 45, Ulm, Germany. albert.ludolph@rku.de
D000690:Amyotrophic Lateral Sclerosis / Q000201:enzymology* / Q000473:pathology / Q000517:prevention & control; D000818:Animals; D004195:Disease Models, Animal; D006801:Humans; D061965:Matrix Metalloproteinase Inhibitors; D020782:Matrix Metalloproteinases / Q000378:metabolism; D051379:Mice; D008822:Mice, Transgenic; D009046:Motor Neurons / Q000187:drug effects / Q000201:enzymology / Q000473:pathology; D020125:Mutation, Missense / Q000235:genetics; D010879:Piperazines / Q000494:pharmacology* / Q000627:therapeutic use; D011743:Pyrimidines / Q000494:pharmacology* / Q000627:therapeutic use; D013482:Superoxide Dismutase / Q000235:genetics / Q000378:metabolism
D061965:Matrix Metalloproteinase Inhibitors; D010879:Piperazines; D011743:Pyrimidines; C453902:Ro 28-2653; C109415:SOD1 G93A protein; D013482:Superoxide Dismutase; D020782:Matrix Metalloproteinases